Comparative Pharmacology
Head-to-head clinical analysis: HEXALEN versus IFEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXALEN versus IFEX.
HEXALEN vs IFEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
IFEX (ifosfamide) is an alkylating agent that crosslinks DNA strands, inhibiting DNA synthesis and transcription. It requires hepatic activation via CYP3A4 to form active metabolites (ifosfamide mustard and acrolein).
260 mg/m2/day orally in 4 divided doses for 14 or 21 days of a 28-day cycle.
1.2 g/m2 intravenously daily for 5 consecutive days every 3 weeks, or 5 g/m2 as a 24-hour continuous infusion every 3 weeks.
None Documented
None Documented
Terminal elimination half-life is 12-13 hours; prolonged to 24 hours in renal impairment.
Terminal elimination half-life is approximately 15 hours in adults with normal renal function; prolonged in renal impairment.
Primarily renal and hepatic metabolism; 60-70% excreted in urine as unchanged drug and metabolites; 15-20% eliminated in feces via biliary secretion.
Renal: approximately 50-70% of the administered dose is excreted in urine as unchanged drug; biliary/fecal excretion is minimal, accounting for less than 5%.
Category C
Category C
Alkylating Agent
Alkylating Agent